Logotipo del repositorio
Logotipo del repositorio
 

Evaluación de la percepción en el uso de betabloqueadores para el tratamiento de la hipertensión arterial antes y después de una intervención educativa: resultados de una encuesta nacional

Vista sencilla de ítem
dc.contributor.authorUrina-Jassir, Daniela
dc.contributor.authorUrina-Triana, Miguel
dc.contributor.authorUrina-Jassir, Manuel
dc.contributor.authorBalaguera-Mendoza, José
dc.contributor.authorMontenegro- Rolong, Luis
dc.contributor.authorUrina-Triana, Manuel
dc.date.accessioned2018-03-08T16:51:12Z
dc.date.available2018-03-08T16:51:12Z
dc.date.issued2017
dc.description.abstractIntroducción: Los betabloqueadores (BB) son utilizados como tratamiento de la hipertensión arterial. Objetivo: Evaluar la percepción del médico general sobre la prescripción de BB en hipertensión arterial, así como el efecto de una intervención educativa sobre dicha percepción. Métodos: En médicos generales que dentro de su actividad atendieran a sujetos con hipertensión arterial, se evaluó la percepción del uso de BB mediante cuestionario que revisó los siguientes aspectos: 1) uso de los BB como fármacos de primera línea, 2) utilización en hipertensos con Diabetes Mellitus Tipo 2, 3) producción de disfunción eréctil, 4) combinación con otros antihipertensivos y 5) control adecuado de la tensión arterial en corto tiempo. Seguidamente se hizo intervención educativa tipo conferencia sobre “Controversias del uso de BB en hipertensión arterial”. Posterior a ella se volvió a aplicar el mismo cuestionario utilizado antes de la misma. Resultados: La encuesta se llevó a cabo en 615 médicos generales en 18 ciudades de Colombia, el promedio de edad de los participantes fue de 38,5 ±7,5, años, con una distribucion por genero de 50,24% hombres y de 49,76% mujeres, el promedio de años de práctica fue de 13,5 ± 9,5 . La percepción a la primera pregunta cambió de 51.27% (Sí) a 88. 4% (Sí) (p = 0.001) y de 48.16% (No) a 10.85% (p = 000001). La segunda de 74,5% (Sí) a 95% (Sí) (p = 0,11) y de 24,84% (No) a 4,42% (No) (p = 0,001). La tercera de 43.05% (Sí) a 19.2% (Sí) (p = 0.002) y de 55.22% (no) a 78.71 (0.042). El cuarto y quinto aspecto evaluados no tuvieron modificaciones. Conclusión: La intervención educativa modificó los tres primeros aspectos evaluados, pero, en los dos últimos, no hubo cambios ya que, desde el principio, los encuestados tenían una percepción de uso elevada.spa
dc.description.abstractIntroduction: Beta-blockers are used in the treatment of hypertension. Objective: The aim of this study was to determine what is the general practitioner perception about the beta blockers prescription, as well as the effect of an educational intervention on this perception. Methods: In general practitioners who attended subjects with arterial hypertension, we evaluated the perception of BB using a questionnaire that reviewed the following aspects: 1) use of BB as first line drugs, 2) use in hypertensive patients with Diabetes Mellitus Type 2, 3) production of erectile dysfunction, 4) combination with other antihypertensives and 5) adequate control of blood pressure in a short time. Later, a conference-type educational intervention was conducted on “Controversies of the use of BB in hypertension”. Subsequently, the same questionnaire used before it was applied again. Results:A total of 615 physicians participated in 18 cities in Colombia, mean age was 38.5 ± 7.5 years, 50.24% were men and 49.76% were women, with 13.5 ± 9.5 years of practice. The perception to the first question changed from 51.27% (Yes) to 88. 4% (Yes) (p= 0.001) and 48.16% (No) to 10.85% (p=000001). The second changed from 74,5% (Yes) to 95 % (Yes) (p=0.11) and from 24.84% (No) to 4.42% (No) (p=0.001). The third from 43.05% (Yes) to 19.2% (Yes)(p=0.002) and from 55.22% (no) to 78.71 (0.042). The fourth and fifth aspect evaluated had no modifications. Conclusions: The educational intervention modified the first three aspects evaluated, but in the last two, there were no changes since, from the beginning, the respondents had a perception of high use.eng
dc.identifier.issn18564550
dc.identifier.urihttp://hdl.handle.net/20.500.12442/1818
dc.language.isospaspa
dc.publisherCooperativa servicios y suministros 212518 RSspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.licenseLicencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacionalspa
dc.sourceRevista Latinoamericana de Hipertensiónspa
dc.sourceVol. 12, No.5 (2017)spa
dc.source.urihttps://www.redalyc.org/articulo.oa?id=170254309007
dc.subjectBetabloqueadoresspa
dc.subjectPercepciónspa
dc.subjectHipertensión Arterial Sistémicaspa
dc.subjectBetablockerseng
dc.subjectPerceptionseng
dc.subjectHypertensioneng
dc.titleEvaluación de la percepción en el uso de betabloqueadores para el tratamiento de la hipertensión arterial antes y después de una intervención educativa: resultados de una encuesta nacionalspa
dc.title.alternativePerception evaluation in the use of beta blockers for the hypertension treatment before and after an educational intervention: results of a national surveyeng
dc.typearticlespa
dcterms.referencesUbel P, Jepson C, Asch D, et al. Misperceptions about beta-blockers and diuretics. A National survey of primary care physicians. J Gen Intern Med 2003; 18:977-983.eng
dcterms.referencesHunt LM, Kreiner M, Brody H. The Changing Face of Chronic Illness Management in Primary Care: A Qualitative Study of Underlying Influences and Unintended Outcomes Ann Fam Med 2012; 10:452-460. doi: 10.1370/afm.1380eng
dcterms.referencesIsaza C, Osorio F, Mesa G, Moncada J. Patrones de uso de antihipertensivos en 11.947 pacientes colombianos. Biomedica 2002; 22:476-485spa
dcterms.referencesGuías Colombianas para el diagnóstico y tratamiento de la hipertensión arterial. Revista Colombiana de Cardiología 2007;13(Suplemento I):187-317spa
dcterms.referencesBangalore S., Messerli F, Kostis, Pepine CJ. Cardiovascular protection using beta-blockers. J Am Coll Cardiol 2007; 50:563-572eng
dcterms.referencesGuía de práctica clínica (GPC) hipertensión arterial primaria. Ministerio de Salud y Protección Social de Colombia. 2013. En: http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Conv_500/GPC_ hta/gpc_hta.aspxspa
dcterms.referencesTask force of the Latin American Society of Hypertension. Guidelines on the management of arterial hypertension and related comorbidities in Latin America. J Hypertens 2017;35(8).eng
dcterms.referencesCorral Y. Diseño de cuestionarios para la recolección de datos. Revista ciencias de la educación 2010;20; 152-168spa
dcterms.referencesOxford Centre for Evidence-based Medicine (CEBM). Centre for Evidence Based Medicine - Levels of Evidence (March 2009). Available from: http://www.cebm.net/index.aspx?o=1025.eng
dcterms.referencesMcNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika, 1947;12:153- 157. DOI: 10.1007/BF02295996eng
dcterms.referencesErdmann E. Safety and tolerabity of beta-blockers: prejudices a reality. European Heart Journal 2009; 11 (supplement A), A21-A25.eng
dcterms.referencesHemmelgarn BR, Chen G, Walker R, McAlister FA, Quan H, Tu K, et al. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. Can J Cardiol. 2008; 24(6): 507–512.eng
dcterms.referencesTamblyn R, Abrahamowicz M, Dauphinee D, Wenghofer E, Jacques A, Klass D, et al. Influence of physicians’ management and communication ability on patients’ persistence with antihypertensive medication. Arch Intern Med. 2010; 170(12): 1064–1072.eng
dcterms.referencesTamblyn R, Huang A, Perreault R, Jacques A, Roy D, Hanley J, et al. The Medical Office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. CMAJ. 2003; 169(6): 549–556.eng
dcterms.referencesTamblyn R, Huang A, Kawasumi Y, Bartlett G, Grad R, Jacques A, et al. The development and evaluation of an integrated electronic prescribing and drug management system for primary care. J Am Med Inform Assoc. 2006; 13(2): 148–159.eng
dcterms.referencesJacoby A, Smith M, Eccles M. A qualitative study to explore influences on general practitioners’ decisions to prescribe new drugs. Br J Gen Pract. 2003; 53:120–125.eng
dcterms.referencesWright JM, Musini VM. First-line drugs for hypertension. Cochrane Database of Syst Rev. 2009; 3: CD001841.eng
dcterms.referencesHyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med. 2000; 160(15): 2281–2286.eng
dcterms.referencesMcGill JB. Optimal use of B-blockers in high-risk hypertension: A guide to dosing equivalence Vasc Health Risk Manag. 201; 6:363-372.eng
dcterms.referencesKronish IM, et al. Meta-Analysis: Impact of drug class on adherence to antihypertensives. Circulation 2011; 123:1611-1621.eng
dcterms.referencesProsser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs - the importance of who says what. Fam Pract. 2003; 20(1): 61–68.eng
dcterms.referencesLindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005; 366:1545–1553.eng
dcterms.referencesVlachopoulos C, Jackson G, Stefanadis C, Montorsi P. Erectile dysfunction in the cardiovascular patient. European Heart Journal 2013; 34:2034-2046.eng
dcterms.referencesSafford R, Monti V, Furberg C, Ma J. Long-term and Short-Term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension 2006; 48:213-218.eng
dcterms.referencesEvidence-Based Guideline for the Management of High Blood Pressure in Adults Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) JAMA. 2014;311(5):507-520.eng
dcterms.referencesWiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD002003. DOI: 10.1002/14651858.CD002003.pub5eng
dcterms.referencesMilchak J, Carter B, James P, Ardery G. Measuring Adherence to Practice Guidelines for the Management of Hypertension An Evaluation of the Literature Hypertension. 2004; 44:602-608.eng
dcterms.referencesHassali MA, Wong ZY, Alrasheedy AA, Saleem F, Mohamad Yahaya AH, Aljadhey H. Does educational intervention improve doctors’ knowledge and perceptions of generic medicines and their generic prescribing rate? A study from Malaysia. SAGE Open Medicine. 2014; 2:2050312114555722. doi:10.1177/2050312114555722.eng
dcterms.referencesCuspidi C, Michev I, Lonati L, Vaccarella A, Cristofari M, Garavelli G, Palumbo G, Meani S, Leonetti G, Magrini F, Zanchetti A; Lombardy Regional Section of Italian Society of Hypertension. Compliance to hypertension guidelines in clinical practice: a multicentre pilot study in Italy. J Hum Hypertens. 2002 Oct;16(10):699-703. https://doi. org/10.1038/sj.jhh.1001468eng
dcterms.referencesQian C, Xiangjie Z, Jie G, Tianhao W, Yuan Z, Shanzhu Z. General practitioners’ hypertension knowledge and training needs: a survey in Xuhui district, Shanghai. BMC Family Practice201314:16 https://doi. org/10.1186/1471-2296-14-16eng
dcterms.referencesMamas T, Panagiotis S, Georgia K, Daphne K, Nikos M, Vasilios P. Physicians’ Perceptions and Adherence to Guidelines for the Management of Hypertension: A National, Multicentre, Prospective Study. International Journal of Hypertension, vol. 2012, Article ID 503821, 11 pages, 2012. doi:10.1155/2012/503821eng

Archivos

Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca